Article History
Received: 19 May 2023
Accepted: 5 July 2023
First Online: 16 August 2023
Declarations
:
: RB: No competing interests to declare. ACA: Spousal shares in Astra Zeneca; Honoraria for advisory boards for MSD, Gilead and Astra Zeneca; Conference fees and travel expenses from Novartis; Research funding from Astra Zeneca paid to institution. SJH: Honoraria for speaking engagements for Pfizer, Novartis and Lilly; Honoraria for advisory boards for Lilly; Joint working agreement with Lilly and Novartis.
: This study was approved as a service evaluation project by the Quality Improvement and Clinical Audit Committee at The Christie NHS Foundation Trust, Manchester, UK on 21-Jun-2021 (Reference Number 22/3030). Service evaluations are exempt from ethics application in the UK according to Human Research Authority guidance.